Literature DB >> 19707744

Differential effects of insulin detemir and neutral protamine Hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes.

F Smeeton1, F Shojaee Moradie, R H Jones, L Westergaard, H Haahr, A M Umpleby, D L Russell-Jones.   

Abstract

AIMS/HYPOTHESIS: We compared the symptoms of hypoglycaemia induced by insulin detemir (NN304) (B29Lys(epsilon-tetradecanoyl),desB30 human insulin) and equally effective doses of neutral protamine Hagedorn (NPH) insulin in relation to possible differential effects on hepatic glucose production and peripheral glucose uptake.
METHODS: After overnight intravenous infusion of soluble human insulin 18 participants with type 1 diabetes received subcutaneous injections of NPH insulin or insulin detemir (0.5 U/kg body weight) on separate occasions in random order. During the ensuing gradual development of hypoglycaemia cognitive function and levels of counter-regulatory hormones were measured and rates of endogenous glucose production and peripheral glucose uptake continuously evaluated using a primed constant infusion of [6,6-(2)H(2)]glucose. The study was terminated when plasma glucose concentration had fallen to 2.4 mmol/l or had reached a minimum at a higher concentration.
RESULTS: During the development of hypoglycaemia no difference between the two insulin preparations was observed in symptoms or hormonal responses. Significant differences were seen in rates of glucose flux. At and below plasma glucose concentrations of 3.5 mmol/l suppression of endogenous glucose production was greater with insulin detemir than with NPH insulin, whereas stimulation of peripheral glucose uptake was greater with NPH insulin than with insulin detemir. CONCLUSIONS/
INTERPRETATION: In participants with type 1 diabetes subcutaneously injected insulin detemir exhibits relative hepatoselectivity compared with NPH insulin, but symptoms of hypoglycaemia and hormonal counter-regulation are similar. TRIAL REGISTRATION: ClinicalTrials.gov NCT00760448.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19707744     DOI: 10.1007/s00125-009-1487-4

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  21 in total

1.  Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans.

Authors:  G A Brunner; G Sendhofer; A Wutte; M Ellmerer; B Søgaard; A Siebenhofer; S Hirschberger; G J Krejs; T R Pieber
Journal:  Exp Clin Endocrinol Diabetes       Date:  2000       Impact factor: 2.949

2.  Novel hepatoselective insulin analog: studies with a covalently linked thyroxyl-insulin complex in humans.

Authors:  F Shojaee-Moradie; J K Powrie; E Sundermann; M W Spring; A Schüttler; P H Sönksen; D Brandenburg; R H Jones
Journal:  Diabetes Care       Date:  2000-08       Impact factor: 19.112

3.  Simulation of IGF-I pharmacokinetics after infusion of recombinant IGF-I in human subjects.

Authors:  M A Boroujerdi; R H Jones; P H Sönksen; D L Russell-Jones
Journal:  Am J Physiol       Date:  1997-08

4.  Measurement of size and turnover rate of body glucose pool by the isotope dilution method.

Authors:  R STEELE; J S WALL; R C DE BODO; N ALTSZULER
Journal:  Am J Physiol       Date:  1956-09

5.  Basal hepatic glucose production is regulated by the portal vein insulin concentration.

Authors:  D K Sindelar; C A Chu; P Venson; E P Donahue; D W Neal; A D Cherrington
Journal:  Diabetes       Date:  1998-04       Impact factor: 9.461

6.  Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp.

Authors:  S V M Hordern; J E Wright; A M Umpleby; F Shojaee-Moradie; J Amiss; D L Russell-Jones
Journal:  Diabetologia       Date:  2005-02-24       Impact factor: 10.122

7.  Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.

Authors:  K Hermansen; S Madsbad; H Perrild; A Kristensen; M Axelsen
Journal:  Diabetes Care       Date:  2001-02       Impact factor: 19.112

8.  Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes.

Authors:  K Kølendorf; G P Ross; I Pavlic-Renar; G Perriello; A Philotheou; J Jendle; M-A Gall; S R Heller
Journal:  Diabet Med       Date:  2006-07       Impact factor: 4.359

9.  The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin.

Authors:  Svend Havelund; Anne Plum; Ulla Ribel; Ib Jonassen; Aage Vølund; Jan Markussen; Peter Kurtzhals
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

10.  Effects of acute insulin excess and deficiency on gluconeogenesis and glycogenolysis in type 1 diabetes.

Authors:  Guenther Boden; Peter Cheung; Carol Homko
Journal:  Diabetes       Date:  2003-01       Impact factor: 9.461

View more
  10 in total

Review 1.  Pursuit of a perfect insulin.

Authors:  Alexander N Zaykov; John P Mayer; Richard D DiMarchi
Journal:  Nat Rev Drug Discov       Date:  2016-03-18       Impact factor: 84.694

2.  Differences in bioactivity between human insulin and insulin analogues approved for therapeutic use- compilation of reports from the past 20 years.

Authors:  Haim Werner; Ernst A Chantelau
Journal:  Diabetol Metab Syndr       Date:  2011-06-29       Impact factor: 3.320

3.  Comparison of insulins detemir and glargine: effects on glucose disposal, hepatic glucose release and the central nervous system.

Authors:  M C Moore; M S Smith; M K Turney; S Boysen; P E Williams
Journal:  Diabetes Obes Metab       Date:  2011-09       Impact factor: 6.577

4.  Central effects of insulin detemir on feeding, body weight, and metabolism in rats.

Authors:  Joseph R Vasselli; F Xavier Pi-Sunyer; Daniel G Wall; Catherine S John; Colin D Chapman; Paul J Currie
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-07-18       Impact factor: 4.310

Review 5.  Insulin detemir: a review of its use in the management of diabetes mellitus.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2012-12-03       Impact factor: 9.546

6.  Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics.

Authors:  Jean-Pierre Le Floch
Journal:  Diabetes Metab Syndr Obes       Date:  2010-06-21       Impact factor: 3.168

7.  Insulin detemir reduces weight gain as a result of reduced food intake in patients with type 1 diabetes.

Authors:  Sunil Zachariah; Ben Sheldon; Fariba Shojaee-Moradie; Nicola C Jackson; Katharine Backhouse; Sigurd Johnsen; Richard H Jones; A Margot Umpleby; David L Russell-Jones
Journal:  Diabetes Care       Date:  2011-05-18       Impact factor: 19.112

8.  Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study.

Authors:  Gerd Koehler; Simon Heller; Stefan Korsatko; Carsten Roepstorff; Søren Rasmussen; Hanne Haahr; Thomas R Pieber
Journal:  Diabetologia       Date:  2013-09-22       Impact factor: 10.122

Review 9.  Weight-sparing effect of insulin detemir: a consequence of central nervous system-mediated reduced energy intake?

Authors:  D Russell-Jones; T Danne; K Hermansen; K Niswender; K Robertson; N Thalange; J R Vasselli; B Yildiz; H U Häring
Journal:  Diabetes Obes Metab       Date:  2015-08-11       Impact factor: 6.577

10.  Changes in glucose and fat metabolism in response to the administration of a hepato-preferential insulin analog.

Authors:  Dale S Edgerton; Mary C Moore; Jason J Winnick; Melanie Scott; Ben Farmer; Helle Naver; Claus B Jeppesen; Peter Madsen; Thomas B Kjeldsen; Erica Nishimura; Christian L Brand; Alan D Cherrington
Journal:  Diabetes       Date:  2014-06-19       Impact factor: 9.461

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.